News
Hosted on MSN14d
Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationFintel reports that on April 8, 2025, Leerink Partners initiated coverage of Spyre Therapeutics (NasdaqGS:SYRE) with a Outperform recommendation. Analyst Price Forecast Suggests 353.70% Upside As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback